文献速递眼底病与葡萄膜炎

一步法与两步法视网膜下注射试验(1,2-SIT):一项比较视网膜下注射后药物回流的随机对照试验

The 1-Step Versus 2-Step Subretinal Injection Trial (1,2-SIT)-A Randomized Controlled Trial to Compare Drug Reflux Following Subretinal Injection.
PubMed 文献 · Am J Ophthalmol · 2025-02-26

该单盲随机对照试验纳入继发于年龄相关性黄斑变性的黄斑下出血患者,比较一步法(n=6)与两步法(n=6)视网膜下注射组织型纤溶酶原激活剂(50 µg/0.1 mL)联合荧光素钠(10 µg/0.1 mL)的药物回流比例。结果显示两种方法的平均回流比例无显著差异,但一步法的回流变异度显著更大;体外实验显示荧光素钠不影响腺相关病毒(AAV)滴度及视网膜祖细胞(RPC)活力,作者认为两步法更有利于保证给药一致性。

要点

  • 一步法与两步法视网膜下注射的平均药物回流比例无显著差异(P = .0155 为方差差异)。
  • 一步法回流的变异度显著大于两步法。
  • 荧光素钠在体外不影响AAV滴度及RPC活力,作者认为两步法更优。

核心结论

  • 视网膜下注射的药物丢失范围为0.4%–19.8%(均值4.3%),一步法与两步法在平均回流比例、手术时长、神经视网膜厚度变化及BCVA变化上无显著差异,但一步法回流的变异度显著大于两步法;0.1 mg/mL荧光素钠不影响AAV产量及RPC活力。
  • 作者认为荧光素钠可作为定量追踪视网膜下AAV基因治疗和视网膜细胞治疗的手段,并认为两步法视网膜下注射优于一步法,以确保给药的一致性。

研究设计与样本

  • 单盲随机对照试验;纳入继发于年龄相关性黄斑变性的黄斑下出血患者,随机分为一步法(n = 6)与两步法(n = 6)视网膜下注射组织型纤溶酶原激活剂(50 µg/0.1 mL)联合荧光素钠(10 µg/0.1 mL)作为光学标记。
  • 所有患者均在玻璃体切除术后于手术结束时行气液交换,随后注入20%六氟化硫气体及贝伐珠单抗;通过对气液交换结束时收集的液体进行荧光光度测定计算回流。
  • 患者每4周接受一次玻璃体腔抗VEGF注射,直至12周最终随访;体外采用实时定量聚合酶链反应测定AAV产量,并用细胞活力试验评估对RPC的影响。

主要发现

  • 一步法视网膜下注射的平均回流为4.8% ± 3.1%(均值 ± 标准误,范围0.4%–19.5%),两步法为3.9% ± 0.9%(范围1.7%–5.3%),均值无显著差异,方差差异P = .0155。
  • 手术时长一步法26.8 ± 1.2分钟 vs 两步法30 ± 2.7分钟,无显著差异;最终视力一步法1.1 ± 0.26(Snellen 20/252)vs 两步法1.1 ± 0.32(Snellen 20/252)logMAR,无显著差异。
  • BCVA变化一步法-0.45 ± 0.27 vs 两步法-0.27 ± 0.23 logMAR,无显著差异;黄斑中心凹厚度一步法139.2 ± 33.2 µm vs 两步法129.8 ± 21.1 µm,无显著差异。
  • 定量聚合酶链反应证实0.1 mg/mL荧光素钠在体外不影响AAV滴度,活力试验提示其不 adverse 影响RPC活力。

关键数值与推荐

  • 一步法视网膜下注射的平均回流为4.8% ± 3.1%(范围0.4%–19.5%),两步法为3.9% ± 0.9%(范围1.7%–5.3%),均值无显著差异,方差差异P = .0155。
  • 手术时长一步法26.8 ± 1.2分钟 vs 两步法30 ± 2.7分钟,无显著差异。
  • 最终视力一步法1.1 ± 0.26(Snellen 20/252)vs 两步法1.1 ± 0.32(Snellen 20/252)logMAR,无显著差异。
  • BCVA变化一步法-0.45 ± 0.27 vs 两步法-0.27 ± 0.23 logMAR,无显著差异;黄斑中心凹厚度一步法139.2 ± 33.2 µm vs 两步法129.8 ± 21.1 µm,无显著差异。

临床怎么用

  • 作者认为荧光素钠可作为定量追踪视网膜下AAV基因治疗和视网膜细胞治疗的合适手段。
  • 作者认为两步法视网膜下注射优于一步法,以确保给药的一致性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate in humans, in vivo, drug retention in the subretinal space following either 1- or 2-step subretinal injection (SRI). DESIGN: A single-masked, randomized, controlled trial. METHODS: Patients presenting with submacular hemorrhage secondary to age-related macular degeneration were randomly allocated to receive subretinal tissue plasminogen activator (50 µg in 0.1 mL) with sodium fluorescein (10 µg in 0.1 mL) as an optical label either as a 1-step (n = 6) procedure, in which the drug defines the subretinal space, or as a 2-step (n = 6) procedure, in which balanced salt solution is first used to define the subretinal space, following pars plana vitrectomy. All patients underwent air-for-fluid exchange at the completion of surgery with subsequent 20% sulfahexafluoride gas and bevacizumab injection. Reflux of subretinally injected drug was calculated by performing fluorophotometry on the fluid collected at the end of air-for-fluid exchange. Patients received intravitreal anti-VEGF at 4-weekly intervals to the final follow-up at 12 weeks. The primary outcome measure was the proportion of drug reflux. Secondary outcomes included duration of surgery, change in visual acuity (VA), final VA, final foveal thickness, and change in foveal thickness. To determine our fluorophotometric technique's applicability to gene and cell therapy, real-time quantitative polymerase chain reaction was employed to determine adeno-associated viral (AAV) yields following exposure to 0.1 mg/mL sodium fluorescein and its effects on retinal progenitor cells (RPCs) was assessed using a cell viability assay. RESULTS: Mean reflux was 4.8% ± 3.1% (mean ± SEM, range 0.4%-19.5%) for 1-step SRI and 3.9% ± 0.9% (range 1.7%-5.3%) for 2-step SRI (no significant difference in means; P = .0155 for the difference in variance). There was no significant difference in the duration of surgery (26.8 ± 1.2 minutes vs 30 ± 2.7 minutes), final VA (1.1 ± 0.26 [Snellen 20/252] vs 1.1 ± 0.32 [Snellen 20/252] logMAR), change in BCVA (-0.45 ± 0.27 vs -0.27 ± 0.23 logMAR) or foveal thickness (139.2 ± 33.2 µm vs 129.8 ± 21.1 µm). Quantitative polymerase chain reaction confirmed that AAV titers are not affected by 0.1 mg/mL sodium fluorescein in vitro, and viability assays suggest that it does not adversely affect RPC viability. CONCLUSIONS: This study demonstrates that drug loss following SRI ranged from 0.4% to 19.8% (mean 4.3%). There is no significant difference between 1-step and 2-step SRI in the mean proportion of drug reflux, duration of surgery, change in neural retinal thickness, or change in BCVA. However, there is a significantly greater variability in reflux for 1-step injection compared to 2-step injection. AAV yields are not affected by 0.1 mg/mL sodium fluorescein, nor is RPC viability. These data suggest that sodium fluorescein may be an appropriate means of tracking subretinal AAV gene therapy and retinal cell therapy quantitatively and that the 2-step SRI approach is preferable to 1-step SRI to ensure consistency in drug delivery.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Simunovic MP, Prime ZJ, Chow RC, et al. The 1-Step Versus 2-Step Subretinal Injection Trial (1,2-SIT)-A Randomized Controlled Trial to Compare Drug Reflux Following Subretinal Injection. Am J Ophthalmol. 2025. PMID: 40020980. doi:10.1016/j.ajo.2025.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。